Head-to-head · WeighScore
MDExam vs Ondra Health
By GLP-1 ScorecardUpdated
Score comparison
Ondra Health has the higher recorded score — 86.8/100 to 55.6/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ondra publishes monthly and prepaid compounded injection plans with pharmacy choices; compare the upfront bill, eligible pharmacy and early-cancellation repricing before choosing a term.
Before you choose
Before comparing the headline prices, the MDExam review and the Ondra Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, MDExam vs Trimi and MDLive vs Ondra Health compare each of them with another graded program, and the list of alternatives to MDExam ranks the programs closest to MDExam on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Collective review covers one graded close to these two, at 71.6/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | MDExam | Ondra Health |
|---|---|---|
| WeighScore | 55.6/100 | 86.8/100 |
| Grade | C | B |
| Site position | #466 | #5 |
| Semaglutide | Program advertised from $225/mo; confirm medication and dose | $149/mo (compounded; month-to-month) |
| Tirzepatide | Specific current price unverified | $219/mo (compounded; month-to-month) |
| Coverage | Coverage not published | Advertises 50 states; pharmacy and formulation eligibility varies |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #466 · C
Strengths
- Publishes a starting program price including medication and coaching
- Describes video visits, nurse access and ongoing treatment adjustments
What to consider
- Starting amount does not establish a specific tirzepatide or all-dose recurring price
- Cash-access marketing and insurance-dependent prescription costs describe different arrangements
- Cancel before the prescription is sent to the pharmacy; no refund after an eligible prescription is transmitted
Strengths
- Publishes monthly charges and separate upfront totals for longer plans
- Allows requests for an eligible pharmacy and formulation, subject to prescribing and availability
- Names independent clinical partners and advertises provider messaging, supplies and shipping
What to consider
- Six- and twelve-month plans require prepayment and an eligible Hallandale or Vials prescription
- Early prepaid cancellation reprices each three-month supply already sent at the regular quarterly rate
- Confirm the selected renewal cutoff and any earned consultation or administrative fees
- Branded and oral access, included lab testing and independent current certification were not established
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.